ribociclib
Selected indexed studies
- Ribociclib plus Endocrine Therapy in Early Breast Cancer. (N Engl J Med, 2024) [PMID:38507751]
- A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. (Ann Oncol, 2025) [PMID:39442617]
- Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (N Engl J Med, 2022) [PMID:35263519]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. (2018) pubmed
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. (2020) pubmed
- Ribociclib plus Endocrine Therapy in Early Breast Cancer. (2024) pubmed
- Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. (2021) pubmed
- A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. (2025) pubmed
- Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) pubmed
- Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. (2022) pubmed
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. (2018) pubmed
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. (2016) pubmed
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. (2018) pubmed